Research highlights both well-studied Siglecs (Siglec-1, -2, -3, -7, and -9) and less characterized members (Siglec-11 and Siglec-XII) as modulators of tumor–immune interactions [13]. The gene discussed is SIGLEC12; the disease is neoplasm.